Research programme: phosphatidylinositol 3-kinase inhibitors - Cerylid

Drug Profile

Research programme: phosphatidylinositol 3-kinase inhibitors - Cerylid

Alternative Names: CBL 1155; CBL 1309; KN 309

Latest Information Update: 07 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerylid Biosciences
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Inflammation; Thrombosis

Most Recent Events

  • 15 Jun 2005 Compounds from this programme are available for licensing (http://www.cerylid.com.au)
  • 17 May 2005 Preclinical trials in Thrombosis in Australia (PO)
  • 17 May 2005 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top